Sugi Predict

Sugi Predict / Compounds / SCHEMBL4336572

SCHEMBL4336572

SCHEMBL4336572

CN1CCN(c2cc(N3CCC(Cc4ccccc4)CC3)c(F)cc2/C=N/NC(N)=S)CC1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ HTT P42858 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ ACHE P22303 2/20 0.40
▸ ALK Q9UM73 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336576 1.00 MAPT (0.42) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL4337057 0.96 MAOB (0.40) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL4337060 0.96 MAOB (0.40) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL4332816 0.93 MCL1 (0.45) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL4332818 0.93 MCL1 (0.45) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL4329400 0.87 MAPT (0.39) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL4329397 0.87 MAPT (0.39) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL13612323 0.87 ALDH1A1 (0.41) MAPTHTTGFERSMN1; SMN2MAOB
SCHEMBL4322348 0.86 MAOB (0.44) MAPTHTTMAOBPOLBMCL1
SCHEMBL4329124 0.86 MAOB (0.44) MAPTHTTMAOBPOLBMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885HTT 2994/4885GFER 540/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885HTT 3282/4885GFER 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.